Abstract
This research develops the TB/non-TB detection and drug-resistant categorization diagnosis decision support system (TB-DRC-DSS). The model is capable of detecting both TB-negative and TB-positive samples, as well as classifying drug-resistant strains and also providing treatment recommendations. The model is developed using a deep learning ensemble model with the various CNN architectures. These architectures include EfficientNetB7, mobileNetV2, and Dense-Net121. The models are heterogeneously assembled to create an effective model for TB-DRC-DSS, utilizing effective image segmentation, augmentation, and decision fusion techniques to improve the classification efficacy of the current model. The web program serves as the platform for determining if a patient is positive or negative for tuberculosis and classifying several types of drug resistance. The constructed model is evaluated and compared to current methods described in the literature. The proposed model was assessed using two datasets of chest X-ray (CXR) images collected from the references. This collection of datasets includes the Portal dataset, the Montgomery County dataset, the Shenzhen dataset, and the Kaggle dataset. Seven thousand and eight images exist across all datasets. The dataset was divided into two subsets: the training dataset (80%) and the test dataset (20%). The computational result revealed that the classification accuracy of DS-TB against DR-TB has improved by an average of 43.3% compared to other methods. The categorization between DS-TB and MDR-TB, DS-TB and XDR-TB, and MDR-TB and XDR-TB was more accurate than with other methods by an average of 28.1%, 6.2%, and 9.4%, respectively. The accuracy of the embedded multiclass model in the web application is 92.6% when evaluated with the test dataset, but 92.8% when evaluated with a random subset selected from the aggregate dataset. In conclusion, 31 medical staff members have evaluated and utilized the online application, and the final user preference score for the web application is 9.52 out of a possible 10.
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference85 articles.
1. World Health Organization (2020). Global Tuberculosis Report 2020, World Health Organization.
2. Pretomanid Development and Its Clinical Roles in Treating Tuberculosis;Fekadu;J. Glob. Antimicrob. Resist.,2022
3. Childhood Tuberculosis: An Overview;Faddoul;Adv. Pediatr.,2015
4. Farrar, J., Hotez, P.J., Junghanss, T., Kang, G., Lalloo, D., and White, N.J. (2013). Manson’s Tropical Diseases, Saunders Ltd.. [23rd ed.].
5. Screening for Latent Tuberculosis Infection Prior to Biologic Therapy in Patients with Chronic Immune-Mediated Inflammatory Diseases (IMID): Interferon-Gamma Release Assay (IGRA) versus Tuberculin Skin Test (TST);Sellami;Egypt. Rheumatol.,2019
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献